Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

News

Two more analyses show efficacy of alirocumab in diabetes

Two more analyses show efficacy of alirocumab in diabetes

Two recent analyses add to the body of evidence supporting the efficacy and tolerability of the PCSK9 inhibitor alirocumab in patients with type 2 diabetes mellitus (T2DM), including those with mixed dyslipidaemia. The first report (1) was a pooled analysis of 5 placebo-controlled Phase 3…

read more »